Third Implantation of Device Firm's Total Artificial Heart That 'Could Save Many Patients Who May Die'
Source: Streetwise Reports  (8/30/21)
An H.C. Wainwright & Co. report noted that Carmat's Aeson implant "could save many patients who may die, due to [a] shortage of donor hearts, while waiting for a heart transplant." More >

Poseida Shares Point Higher After FDA Clears NDA for Relapsed/Refractory Multiple Myeloma Treatment Candidate
Source: Streetwise Reports  (8/30/21)
Shares of Poseida Therapeutics traded 10% higher after the company reported that the U.S. Food and Drug Administration granted clearance for its Investigational New Drug Application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for use in treating relapsed/refractory multiple myeloma. More >

Bolt Bio Partners With Innovent Biologics to Create Three New Cancer Treatments
Source: Streetwise Reports  (8/28/21)
Shares of Bolt Biotherapeutics Inc. traded nearly 10% higher after the company reported it is collaborating with Innovent Biologics to develop three new oncology Boltbodyâ„¢ ISAC programs. More >

Dermatological Device Company to Acquire Laser System Firm
Source: Streetwise Reports  (8/24/21)
An H.C. Wainwright report noted that "this deal is an opportunity for STRATA Skin Sciences to substantially increase its long-term, recurring revenue base." More >

With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon
Source: Streetwise Reports  (8/24/21)
A BTIG report noted that Legend Biotech's cilta-cel has the potential "to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class profile." More >

Biopharma's Amino Acid Compound Shows Anti-Inflammatory Effect
Source: Streetwise Reports  (8/23/21)
Studies suggest that Galmed Pharmaceuticals' Amilo-5MER has "therapeutic potential in a number of inflammatory diseases," according to an H.C. Wainwright & Co. report. More >

Trillium Receives US$2.26B Buyout Bid, Shares Trade 190% Higher
Source: Streetwise Reports  (8/23/21)
Trillium Therapeutics shares traded 190% higher after the company reported it agreed to be acquired by pharmaceutical giant Pfizer Inc. for $18.50 per share in cash. More >

Specialty Pharma's Q2/21 Results 'Fundamentally Ahead of Expectations'
Source: Streetwise Reports  (8/23/21)
A ROTH Capital Partners report noted that Assertio Therapeutics' business model is starting to gain traction. More >

Flora Shares Sprout Higher on H1 Financial Results and Positive FY Sales Outlook
Source: Streetwise Reports  (8/20/21)
Shares of natural cannabis firm Flora Growth Corp. rose 43% after the company reported H1/21 financial results and indicated it expects H2/21 revenues will be in the range of US$9-11 million. More >

Inovalon Receives $7.3 Billion Buyout Offer From Nordic Capital Led Equity Consortium
Source: Streetwise Reports  (8/19/21)
Inovalon Holdings Inc. shares traded 8% higher after the cloud healthcare technology platform firm reported it entered into an agreement to be acquired by an equity consortium led by Nordic Capital and Insight Partners for $41.00 per share in cash. More >

Biotech Offering Significant Return Potential Advances Lead Breast Cancer Trials
Source: Streetwise Reports  (8/18/21)
An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected. More >

Global Specialty Pharma Co. Strongly Beats on Consensus Q2 Revenue and Earnings Estimates
Source: Streetwise Reports  (8/18/21)
Paradigm Capital Inc. stated in a research report that Knight Therapeutics Inc. posted significantly better than expected operating and financial results in Q2/21 that greatly exceeded analysts' estimates. Meanwhile, insiders continue to add to their positions, and the company has filed a new NCIB allowing it to purchase up to 10% of the float during the next 12 months. More >

Platform Therapeutics Co. Posts Positive Revenue Surprise in Q2 on Higher Dermatology Product Sales
Source: Streetwise Reports  (8/18/21)
Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.'s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a "Buy" rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential. More >

Diagnostics Firm Readies for Pivotal FDA Study of Device That Detects Bacterial Lung Infections
Source: Streetwise Reports  (8/18/21)
Promising early results and a new line of equity support Avisa Diagnostic’s drive for IDE approval of its rapid-response breath test for pneumonia, TB, CF, and other lung ailments. More >

Cannabis Products Retailer Achieves Record Sales in Q3 FY21
Source: Streetwise Reports  (8/17/21)
Gross sales of Stem Holdings dba Driven by Stem during the quarter were 104% higher than they were a year ago. More >

Travere Posts Positive Topline Data in Phase 3 IgA Nephropathy Study, Shares Trade Higher
Source: Streetwise Reports  (8/16/21)
Travere Therapeutics shares traded 14% higher after the company reported positive interim results from its ongoing Phase 3 PROTECT study of sparsentan in treating IgA nephropathy, a chronic kidney disease that can lead to end-stage renal disease. More >

Clover Health Shares Grow 12% after Posting Q2 Earnings and 229% Platform User Growth
Source: Streetwise Reports  (8/12/21)
Shares of Clover Health Investments Corp. traded higher after the company reported Q2/21 financial results that included a 140% increase in YoY revenue. More >

Coverage Initiated on Developer of Treatment for Myelofibrosis, GvHD, COVID-19
Source: Streetwise Reports  (8/11/21)
A BTIG report noted that CTI Biopharma's Pacritinib "has the potential to be a lead therapeutic in the myelofibrosis space and in additional indications that could provide material value to CTI and CTI's shares over time." More >

U.S. Cannabis Sector to Show 'Secular Growth With Margin Improvements,' Analyst Says
Source: Streetwise Reports  (8/11/21)
Behind that forecast, in part, are positive cannabis legislative developments and increasing consumer cannabis use, which are covered in a ROTH Capital Partners report. More >

Liquid Avatar Unveils New App to Confirm COVID-19 Testing Status, Reduce New Outbreaks of the Pandemic
Source: Streetwise Reports  (8/11/21)
The Liquid Avatar Credential Ecosystem, or LAVCE, is designed to carry a secure, digital record of a person’s verifiable COVID-19 testing credentials, and future healthcare applications of the technology are expected. More >

Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College
Source: Streetwise Reports  (8/10/21)
Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors. More >

Fulcrum Shares Soar on Positive Interim Data in Phase 1 Sickle Cell Disease Study
Source: Streetwise Reports  (8/10/21)
Fulcrum Therapeutics shares rose 125% and set a new 52-week high after the company reported Q2/21 financial results and released positive interim results from its Phase 1 sickle cell disease trial. More >

Cortexyme Expects to Release Positive Topline Data from Ph. 2/3 Alzheimer's Trial by Late Autumn
Source: Streetwise Reports  (8/9/21)
Shares of Cortexyme Inc. traded 47% higher to a new 52-week high after the company reported Q2/21 financial results and provided an update regarding its ongoing Alzheimer's and periodontal disease clinical trials. More >

STAAR Shares Burst Higher after Firm Posts 77% Increase in Q2 Net Sales and Raises FY Outlook
Source: Streetwise Reports  (8/6/21)
Shares of STAAR Surgical Co. traded 20% higher after the company reported Q2/21 financial results highlighting a 93% YoY increase in net sales of its Implantable Collamer® Lenses. More >

US-Based Biopharma 'In Full Reset Mode,' Analyst Says
Source: Streetwise Reports  (8/4/21)
An H.C. Wainwright & Co. report notes that Agios Pharmaceuticals "is rapidly rebooting and has made critical progress on various fronts." More >